Blockade	O
of	O
myeloid	B-GP
differentiation	I-GP
protein	I-GP
2	I-GP
prevents	O
obesity	B-DS
‐	O
induced	O
inflammation	O
and	O
nephropathy	B-DS

These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Abstract	O

Obesity	B-DS
is	O
a	O
major	O
and	O
independent	O
risk	O
factor	O
of	O
kidney	B-DS
diseases	I-DS
.	O

The	O
pathogenic	O
mechanisms	O
of	O
obesity	B-DS
‐	O
associated	O
renal	O
injury	O
are	O
recognized	O
to	O
at	O
least	O
involve	O
a	O
lipid	O
‐	O
rich	O
and	O
pro	O
‐	O
inflammatory	O
state	O
of	O
the	O
renal	O
tissues	O
,	O
but	O
specific	O
mechanisms	O
establishing	O
causal	O
relation	O
remain	O
unknown	O
.	O

Saturated	O
fatty	O
acids	O
are	O
elevated	O
in	O
obesity	B-DS
,	O
and	O
known	O
to	O
induce	O
chronic	O
inflammation	O
in	O
kidneys	O
.	O

Myeloid	B-GP
differentiation	I-GP
protein	I-GP
2	I-GP
(	O
MD2	B-GP
)	O
is	O
an	O
important	O
protein	O
in	O
lipopolysaccharide	O
‐	O
induced	O
innate	O
immunity	O
response	O
and	O
inflammation	O
.	O

We	O
suggested	O
that	O
obesity	B-DS
‐	O
associated	O
renal	O
injury	O
is	O
regulated	O
by	O
MD2	B-GP
thereby	O
driving	O
an	O
inflammatory	O
renal	O
injury	O
.	O

The	O
used	O
three	O
mouse	B-OG
models	O
for	O
in	O
vivo	O
study	O
:	O
MD2	B-GP
knockout	O
mice	B-OG
(	O
KO	O
)	O
maintained	O
on	O
high	O
fat	O
diet	O
(	O
HFD	O
),	O
wild	O
‐	O
type	O
mice	B-OG
on	O
HFD	O
plus	O
L6H21	O
,	O
a	O
specific	O
MD2	B-GP
inhibitor	O
and	O
KO	O
mice	B-OG
given	O
palmitic	O
acid	O
(	O
PA	O
)	O
by	O
IV	O
injection	O
.	O

The	O
in	O
vitro	O
studies	O
were	O
carried	O
out	O
in	O
cultured	O
renal	O
tubular	O
epithelial	O
cells	O
,	O
mouse	B-OG
mesangial	O
cells	O
and	O
primary	O
macrophages	O
,	O
respectively	O
.	O

The	O
HFD	O
mice	B-OG
presented	O
with	O
increased	O
hyperlipidemia	B-DS
,	O
serum	O
creatinine	O
and	O
proteinuria	O
.	O

Renal	O
tissue	O
from	O
HFD	O
mice	B-OG
had	O
increased	O
fibrosis	O
,	O
inflammatory	B-GP
cytokines	I-GP
,	O
macrophage	O
infiltration	O
,	O
and	O
activation	O
of	O
NF	B-GP
‐	I-GP
κB	I-GP
and	O
MAPKs	B-GP
.	O

This	O
HFD	O
‐	O
induced	O
renal	O
injury	O
profile	O
was	O
not	O
observed	O
in	O
KO	O
mice	B-OG
or	O
L6H21	O
‐	O
treated	O
mice	B-OG
.	O

Mice	B-OG
given	O
PA	O
mimmicked	O
the	O
HFD	O
‐	O
induced	O
renal	O
injury	O
profiles	O
,	O
which	O
were	O
prevented	O
by	O
MD2	B-GP
knockout	O
.	O

The	O
in	O
vitro	O
data	O
further	O
confirmed	O
MD2	B-GP
mediates	O
PA	O
‐	O
induced	O
inflammation	O
.	O
MD2	B-GP
is	O
causally	O
related	O
with	O
obesity	B-DS
‐	O
associated	O
renal	O
inflammatory	O
injury	O
.	O

We	O
believe	O
that	O
MD2	B-GP
is	O
an	O
attractive	O
target	O
for	O
future	O
therapeutic	O
strategies	O
in	O
obesity	B-DS
‐	O
associated	O
kidney	B-DS
diseases	I-DS
.	O

Introduction	O

In	O
recent	O
years	O
,	O
epidemiological	O
and	O
clinical	O
studies	O
have	O
linked	O
obesity	B-DS
to	O
the	O
development	O
and	O
progression	O
of	O
kidney	O
injury	O
.	O

Obesity	B-DS
is	O
considered	O
an	O
important	O
factor	O
for	O
developing	O
end	O
‐	O
stage	O
renal	B-DS
disease	I-DS
,	O
behind	O
only	O
to	O
proteinuria	O
1	O
,	O
2	O
,	O
3	O
.	O

Obesity	B-DS
‐	O
associated	O
kidney	O
injury	O
in	O
human	B-OG
subjects	O
is	O
characterized	O
by	O
structural	O
remodelling	O
of	O
the	O
kidney	O
tissue	O
and	O
includes	O
tubular	O
atrophy	O
,	O
interstitial	O
fibrosis	O
,	O
arterial	B-DS
sclerosis	I-DS
and	O
glomerulomegaly	B-DS
2	O
,	O
4	O
.	O

While	O
obesity	B-DS
is	O
clearly	O
related	O
to	O
kidney	O
injury	O
,	O
the	O
pathophysiological	O
mechanisms	O
are	O
far	O
from	O
clear	O
.	O

A	O
persistent	O
and	O
crucial	O
component	O
of	O
obesity	B-DS
‐	O
related	O
tissue	O
injury	O
is	O
chronic	O
inflammation	O
resulting	O
from	O
the	O
production	O
of	O
pro	O
‐	O
inflammatory	O
molecules	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
and	O
macrophage	O
infiltration	O
10	O
,	O
11	O
.	O

In	O
the	O
kidneys	O
of	O
obese	O
animal	B-OG
models	O
,	O
preventing	O
inflammation	O
protects	O
against	O
renal	O
dysfunction	O
and	O
tissue	O
remodelling	O
9	O
,	O
11	O
.	O

A	O
major	O
driver	O
of	O
inflammation	O
in	O
obesity	B-DS
is	O
elevated	O
levels	O
of	O
saturated	O
free	O
fatty	O
acids	O
(	O
SFAs	O
)	O
12	O
,	O
13	O
.	O

SFAs	O
including	O
lauric	O
acid	O
(	O
C12	O
:	O
0	O
),	O
PA	O
(	O
C16	O
:	O
0	O
)	O
and	O
stearic	O
acid	O
(	O
C18	O
:	O
0	O
)	O
are	O
pro	O
‐	O
inflammatory	O
lipid	O
compounds	O
known	O
to	O
activate	O
inflammatory	O
signalling	O
in	O
a	O
wide	O
range	O
of	O
cells	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
.	O

PA	O
is	O
the	O
most	O
abundant	O
SFA	O
in	O
blood	O
,	O
and	O
the	O
most	O
studied	O
in	O
the	O
pathogenesis	O
of	O
the	O
metabolic	B-DS
syndrome	I-DS
,	O
insulin	B-GP
resistance	O
and	O
vascular	B-DS
disorders	I-DS
8	O
,	O
13	O
,	O
14	O
,	O
19	O
,	O
20	O
.	O

We	O
11	O
and	O
others	O
8	O
,	O
16	O
have	O
shown	O
that	O
PA	O
is	O
a	O
potent	O
stimulus	O
for	O
the	O
production	O
of	O
cytokines	B-GP
,	O
adhesion	B-GP
molecules	I-GP
,	O
as	O
well	O
as	O
activation	O
of	O
nuclear	B-GP
factor	I-GP
‐	I-GP
κB	I-GP
(	O
NF	B-GP
‐	I-GP
κB	I-GP
).	O

Recent	O
studies	O
have	O
shown	O
that	O
elevated	O
SFAs	O
may	O
initiate	O
inflammatory	O
injury	O
through	O
activating	O
toll	B-GP
‐	I-GP
like	I-GP
receptor	I-GP
4	I-GP
(	O
TLR4	B-GP
)	O
21	O
.	O

TLR4	B-GP
is	O
a	O
critical	O
pattern	B-GP
recognition	I-GP
receptor	I-GP
and	O
is	O
well	O
known	O
for	O
recognizing	O
lipopolysaccharide	O
(	O
LPS	O
),	O
a	O
component	O
of	O
Gram	B-OG
‐	I-OG
negative	I-OG
bacteria	I-OG
22	O
.	O

The	O
LPS	O
response	O
requires	O
a	O
mediating	O
protein	O
called	O
MD2	B-GP
.	O

Upon	O
binding	O
to	O
LPS	O
,	O
the	O
LPS	O
‐	O
MD2	B-GP
‐	O
TLR4	B-GP
complex	O
forms	O
and	O
activates	O
downstream	O
pro	O
‐	O
inflammatory	O
signalling	O
cascades	O
,	O
leading	O
to	O
the	O
activation	O
of	O
NF	B-GP
‐	I-GP
κB	I-GP
,	O
activating	B-GP
protein	I-GP
‐	I-GP
1	I-GP
(	O
AP	B-GP
‐	I-GP
1	I-GP
)	O
and	O
mitogen	B-GP
‐	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	O
MAPK	B-GP
)	O
23	O
,	O
and	O
then	O
induces	O
cytokines	B-GP
such	O
as	O
tumour	B-GP
necrosis	I-GP
factor	I-GP
‐	I-GP
α	I-GP
(	O
TNF	B-GP
‐	I-GP
α	I-GP
),	O
interleukin	B-GP
‐	I-GP
(	I-GP
IL	I-GP
)	I-GP
1β	I-GP
,	O
IL	B-GP
‐	I-GP
6	I-GP
and	O
interferon	B-GP
‐	I-GP
γ	I-GP
(	O
IFN	B-GP
‐	I-GP
γ	I-GP
)	O
15	O
,	O
24	O
,	O
25	O
,	O
26	O
,	O
27	O
.	O

MD2	B-GP
plays	O
an	O
important	O
role	O
in	O
LPS	O
‐	O
induced	O
innate	O
immunity	O
and	O
inflammation	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
MD2	B-GP
is	O
required	O
in	O
SFA	O
/	O
obesity	B-DS
‐	O
induced	O
inflammation	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
causal	O
relation	O
of	O
MD2	B-GP
in	O
renal	O
inflammatory	O
injury	O
in	O
the	O
HFD	O
‐	O
induced	O
model	O
of	O
obesity	B-DS
,	O
PA	O
‐	O
challenged	O
mice	B-OG
,	O
and	O
cultured	O
renal	O
cells	O
.	O

We	O
demonstrate	O
that	O
MD2	B-GP
is	O
an	O
important	O
regulator	O
of	O
HFD	O
‐	O
and	O
SFA	O
‐	O
induced	O
renal	O
inflammatory	O
injury	O
.	O

Materials	O
and	O
methods	O

PA	O
and	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	B-GP
)	O
were	O
purchased	O
from	O
Sigma	O
‐	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

MD2	B-GP
neutralizing	O
antibody	B-GP
(	O
anti	O
‐	O
MD2	B-GP
)	O
was	O
purchased	O
from	O
InvivoGen	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
).	O

Compound	O
L6H21	O
was	O
prepared	O
with	O
a	O
purity	O
of	O
99	O
.	O
2	O
%	O
as	O
described	O
in	O
our	O
previous	O
study	O
28	O
,	O
29	O
.	O

L6H21	O
were	O
dissolved	O
in	O
DMSO	O
for	O
in	O
vitro	O
experiments	O
and	O
in	O
1	O
%	O
sodium	O
carboxyl	O
methyl	O
cellulose	O
(	O
CMC	O
‐	O
Na	O
)	O
for	O
in	O
vivo	O
experiments	O
.	O

Antibodies	B-GP
for	O
GAPDH	B-GP
,	O
p38	B-GP
,	O
p	O
‐	O
p38	B-GP
,	O
JNK	B-GP
and	O
p	O
‐	O
JNK	B-GP
were	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Danvers	O
,	O
MA	O
,	O
USA	O
).	O

Antibodies	B-GP
for	O
IκB	B-GP
‐	I-GP
α	I-GP
,	O
p	O
‐	O
IκB	B-GP
‐	I-GP
α	I-GP
,	O
MD2	B-GP
,	O
ERK	B-GP
,	O
p	O
‐	O
ERK	B-GP
,	O
TGF	B-GP
‐	I-GP
β1	I-GP
,	O
Collagen	B-GP
IV	I-GP
,	O
NF	B-GP
‐	I-GP
κB	I-GP
p65	B-GP
,	O
VCAM	B-GP
‐	I-GP
1	I-GP
,	O
Lamin	B-GP
B	I-GP
,	O
CD68	B-GP
,	O
MCP	B-GP
‐	I-GP
1	I-GP
,	O
TLR4	B-GP
and	O
CD68	B-GP
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
).	O

Secondary	O
antibodies	B-GP
were	O
also	O
obtained	O
from	O
Santa	O
Cruz	O
.	O

Mesangial	O
cells	O
(	O
SV40	B-OG
MES	O
13	O
,	O
ATCC	O
‐	O
CRL	O
‐	O
1927	O
)	O
and	O
tubular	O
epithelial	O
cells	O
(	O
NRK	O
‐	O
52E	O
,	O
ATCC	O
‐	O
CRL	O
‐	O
1571	O
)	O
were	O
obtained	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
,	O
USA	O
).	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
under	O
a	O
humidified	O
5	O
%	O
CO2	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
(	O
Gibco	O
,	O
Eggenstein	O
,	O
Germany	O
)	O
containing	O
5	O
.	O
5	O
mM	O
D	O
‐	O
glucose	O
(	O
low	O
glucose	O
,	O
LG	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Gibco	O
),	O
100	O
U	O
/	O
ml	O
penicillin	O
and	O
100	O
U	O
/	O
ml	O
streptomycin	O
.	O

Animal	B-OG
studies	O

Male	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
(	O
8	O
weeks	O
old	O
,	O
weighing	O
18	O
–	O
20	O
g	O
)	O
were	O
purchased	O
from	O
SLAC	O
Laboratory	O
Animal	B-OG
Center	O
(	O
Shanghai	O
,	O
China	O
).	O

Male	O
MD2	B-GP
−/−	O
mice	B-OG
(	O
B6	O
.	O
129P2	O
‐	O
Ly96	O
KO	O
)	O
on	O
a	O
C57BL	O
/	O
6	O
background	O
were	O
purchased	O
from	O
Riken	O
BioResource	O
Center	O
(	O
Tsukuba	O
,	O
Ibaraki	O
,	O
Japan	O
).	O

All	O
animal	B-OG
care	O
and	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
Wenzhou	O
Medical	O
University	O
Animal	B-OG
Policy	O
and	O
Welfare	O
Committee	O
.	O

HFD	O
model	O
of	O
obesity	B-DS

Male	O
wild	O
‐	O
type	O
(	O
C57BL	O
/	O
6	O
)	O
and	O
MD2	B-GP
−\−	O
(	O
KO	O
)	O
mice	B-OG
were	O
fed	O
a	O
HFD	O
or	O
normal	O
control	O
diet	O
(	O
ctrol	O
)	O
for	O
4	O
months	O
.	O

Body	O
weights	O
were	O
recorded	O
weekly	O
and	O
at	O
the	O
end	O
of	O
the	O
4	O
‐	O
month	O
study	O
.	O

Normal	O
control	O
diet	O
was	O
purchased	O
from	O
MediScience	O
Diets	O
Co	O
.	O

LTD	O
,	O
Yangzhou	O
,	O
China	O
,	O
containing	O
10	O
kcal	O
.%	O
fat	O
,	O
20	O
kcal	O
.%	O
protein	O
and	O
70	O
kcal	O
.%	O
carbohydrate	O
(	O
Cat	O
.	O
#	O
MD12031	O
);	O
HFD	O
was	O
purchased	O
from	O
the	O
same	O
company	O
(	O
Cat	O
.	O
#	O
MD12033	O
)	O
containing	O
60	O
kcal	O
.%	O
fat	O
,	O
20	O
kcal	O
.%	O
protein	O
and	O
20	O
kcal	O
.%	O
carbohydrate	O
.	O

The	O
role	O
of	O
MD2	B-GP
was	O
also	O
examined	O
in	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
treated	O
with	O
MD2	B-GP
inhibitor	O
L6H21	O
.	O

For	O
these	O
studies	O
,	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
on	O
control	O
diet	O
or	O
HFD	O
(	O
2	O
‐	O
month	O
duration	O
)	O
were	O
treated	O
with	O
20	O
mg	O
/	O
kg	O
of	O
L6H21	O
(	O
HFD	O
‐	O
L6H21	O
)	O
or	O
1	O
%	O
CMC	O
‐	O
Na	O
solution	O
(	O
control	O
)	O
once	O
every	O
2	O
days	O
by	O
oral	O
gavage	O
for	O
2	O
months	O
,	O
while	O
maintained	O
on	O
their	O
respective	O
diets	O
.	O

An	O
additional	O
group	O
of	O
mice	B-OG
was	O
administered	O
with	O
curcumin	O
(	O
50	O
mg	O
/	O
kg	O
)	O
as	O
positive	O
control	O
.	O

PA	O
challenge	O
model	O

Male	O
C57BL	O
/	O
6	O
and	O
MD2	B-GP
−/−	O
mice	B-OG
were	O
injected	O
with	O
300	O
μl	O
of	O
PA	O
(	O
5	O
mM	O
),	O
normal	O
saline	O
control	O
(	O
NS	O
)	O
or	O
BSA	O
vehicle	O
control	O
by	O
tail	O
vein	O
twice	O
daily	O
for	O
2	O
weeks	O
.	O

At	O
the	O
end	O
of	O
treatment	O
period	O
,	O
mice	B-OG
were	O
killed	O
,	O
and	O
urine	O
,	O
blood	O
and	O
kidney	O
tissues	O
were	O
collected	O
.	O

Kidney	O
tissues	O
were	O
weighed	O
and	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
morphological	O
analysis	O
or	O
snap	O
‐	O
frozen	O
in	O
liquid	O
nitrogen	O
for	O
gene	O
and	O
protein	O
expression	O
analyses	O
.	O

Serum	O
and	O
urine	O
samples	O
were	O
stored	O
in	O
−	O
80	O
°	O
C	O
.	O

Additional	O
methods	O

Routine	O
methods	O
including	O
biochemical	O
measurement	O
,	O
cell	O
culture	O
,	O
isolation	O
and	O
culture	O
of	O
primary	O
macrophages	O
from	O
rats	B-OG
or	O
mice	B-OG
,	O
macrophage	O
adhesion	O
assay	O
,	O
Western	O
blotting	O
,	O
immunohistochemistry	O
,	O
real	O
‐	O
time	O
qPCR	O
and	O
primers	O
used	O
for	O
real	O
‐	O
time	O
qPCR	O
assay	O
(	O
Table	O
S1	O
)	O
are	O
described	O
in	O
details	O
in	O
the	O
Supplementary	O
File	O
.	O

Statistical	O
analysis	O

Data	O
were	O
presented	O
as	O
means	O
±	O
S	O
.	O
E	O
.	O
M	O
.	O

Differences	O
were	O
detected	O
by	O
Student	O
'	O
s	O
t	O
‐	O
test	O
or	O
anova	O
multiple	O
comparisons	O
as	O
appropriate	O
using	O
GraphPad	O
Pro	O
(	O
GraphPad	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
).	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Results	O

MD2	B-GP
deficiency	O
prevents	O
renal	B-DS
inflammation	I-DS
and	O
injuries	O
in	O
the	O
HFD	O
‐	O
induced	O
model	O
of	O
obesity	B-DS

To	O
study	O
the	O
potential	O
role	O
of	O
MD2	B-GP
in	O
obesity	B-DS
‐	O
associated	O
renal	O
injury	O
,	O
we	O
utilized	O
the	O
HFD	O
‐	O
induced	O
model	O
of	O
obesity	B-DS
30	O
,	O
31	O
.	O

We	O
first	O
examined	O
whether	O
the	O
expression	O
and	O
activity	O
of	O
MD2	B-GP
are	O
altered	O
in	O
the	O
kidney	O
tissues	O
of	O
HFD	O
‐	O
fed	O
mice	B-OG
.	O

Our	O
results	O
show	O
that	O
4	O
months	O
of	O
HFD	O
feeding	O
induced	O
MD2	B-GP
expression	O
and	O
MD2	B-GP
/	O
TLR4	B-GP
complex	O
formation	O
in	O
the	O
kidney	O
tissues	O
(	O
Fig	O
.	O
S1	O
).	O

We	O
then	O
subjected	O
MD2	B-GP
−/−	O
mice	B-OG
to	O
the	O
same	O
HFD	O
regimen	O
for	O
4	O
months	O
.	O

Maintaining	O
wild	O
‐	O
type	O
C57BL	O
/	O
6	O
(	O
B6	O
)	O
and	O
MD2	B-GP
−\−	O
(	O
KO	O
)	O
mice	B-OG
on	O
HFD	O
resulted	O
in	O
an	O
increased	O
weight	O
gain	O
compared	O
to	O
mice	B-OG
fed	O
a	O
control	O
diet	O
(	O
Fig	O
.	O
1A	O
).	O

However	O
,	O
analysis	O
of	O
kidney	O
tissues	O
revealed	O
that	O
only	O
B6	B-OG
mice	I-OG
had	O
increased	O
kidney	O
to	O
body	O
weight	O
ratio	O
(	O
KW	O
/	O
BW	O
)	O
but	O
not	O
MD2	B-GP
‐	O
KO	O
mice	B-OG
(	O
Fig	O
.	O
1B	O
).	O

B6	O
‐	O
HFD	O
mice	B-OG
also	O
presented	O
with	O
hyperlipidemia	B-DS
as	O
indicated	O
by	O
increased	O
circulating	O
low	O
‐	O
density	O
lipoproteins	O
(	O
LDL	O
),	O
triglycerides	O
(	O
TG	O
)	O
and	O
total	O
cholesterol	O
(	O
TCH	O
)	O
(	O
Fig	O
.	O
S2	O
).	O

KO	O
‐	O
HFD	O
mice	B-OG
showed	O
similar	O
increases	O
in	O
the	O
lipids	O
except	O
for	O
TG	O
,	O
which	O
did	O
not	O
show	O
any	O
alteration	O
compared	O
to	O
KO	O
mice	B-OG
on	O
control	O
diet	O
(	O
Fig	O
.	O
S2B	O
).	O

MD2	B-GP
knockout	O
mice	B-OG
are	O
protected	O
against	O
high	O
fat	O
diet	O
‐	O
induced	O
renal	O
dysfunction	O
.	O

Wild	O
‐	O
type	O
(	O
B6	O
)	O
and	O
MD2	B-GP
−/−	O
(	O
KO	O
)	O
mice	B-OG
were	O
fed	O
a	O
HFD	O
or	O
control	O
diet	O
(	O
Ctrol	O
)	O
for	O
4	O
months	O
,	O
and	O
kidney	O
tissues	O
were	O
evaluated	O
for	O
inflammatory	O
injury	O
.	O

(	O
A	O
)	O
Body	O
weights	O
of	O
mice	B-OG
fed	O
Ctrol	O
and	O
HFD	O
.	O

(	O
B	O
)	O
Kidney	O
weights	O
normalized	O
to	O
body	O
weight	O
.	O

(	O
C	O
)	O
Serum	O
BUN	O
levels	O
.	O

(	O
D	O
)	O
Serum	O
creatinine	O
levels	O
.	O

(	O
E	O
)	O
Representative	O
microscopic	O
images	O
showing	O
H	O
&	O
E	O
,	O
Sirius	O
Red	O
(	O
red	O
colour	O
),	O
PAS	O
(	O
purple	O
colour	O
)	O
and	O
Masson	O
'	O
s	O
trichrome	O
(	O
blue	O
colour	O
)	O
staining	O
.	O

The	O
quantitative	O
data	O
for	O
1E	O
were	O
shown	O
in	O
the	O
Figure	O
S3	O
.	O

[	O
means	O
±	O
S	O
.	O
E	O
.	O
M	O
.;	O
n	O
=	O
7	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
B6	O
‐	O
HFD	O
versus	O
KO	O
‐	O
HFD	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
,	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
###	O
P	O
<	O
0	O
.	O
001	O
,	O
B6	O
‐	O
Ctrol	O
versus	O
B6	O
‐	O
HFD	O
].	O

Analysis	O
of	O
renal	O
function	O
parameters	O
showed	O
that	O
HFD	O
feeding	O
increased	O
serum	O
levels	O
of	O
creatinine	O
and	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
in	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
1C	O
and	O
D	O
)	O
compared	O
to	O
mice	B-OG
on	O
control	O
diet	O
.	O

However	O
,	O
BUN	O
and	O
creatinine	O
did	O
not	O
show	O
any	O
alteration	O
in	O
the	O
KO	O
‐	O
HFD	O
mice	B-OG
indicating	O
preserved	O
kidney	O
function	O
.	O

These	O
results	O
indicate	O
preserved	O
renal	O
function	O
in	O
MD2	B-GP
−/−	O
mice	B-OG
fed	O
a	O
HFD	O
.	O

We	O
next	O
examined	O
structural	O
alterations	O
in	O
the	O
kidney	O
tissues	O
of	O
HFD	O
‐	O
fed	O
mice	B-OG
using	O
immunohistological	O
staining	O
(	O
Fig	O
.	O
1E	O
and	O
Fig	O
.	O
S3	O
).	O

Kidney	O
tissues	O
from	O
B6	O
‐	O
HFD	O
mice	B-OG
showed	O
increased	O
deposition	O
of	O
connective	O
tissue	O
within	O
glomeruli	O
,	O
interstitial	O
‐	O
tubular	O
region	O
and	O
in	O
the	O
Bowman	O
'	O
s	O
capsule	O
as	O
detected	O
by	O
Masson	O
'	O
s	O
trichrome	O
and	O
Sirius	O
red	O
staining	O
.	O

Periodic	O
Acid	O
‐	O
Schiff	O
(	O
PAS	O
),	O
another	O
commonly	O
used	O
connective	O
tissue	O
stain	O
,	O
showed	O
similar	O
results	O
.	O

These	O
features	O
are	O
consistent	O
with	O
our	O
previous	O
study	O
11	O
and	O
are	O
indicative	O
of	O
increased	O
mesangial	O
matrix	O
expansion	O
seen	O
in	O
obesity	B-DS
‐	O
associated	O
renal	O
injury	O
2	O
,	O
10	O
.	O

Interestingly	O
,	O
this	O
tissue	O
remodelling	O
activity	O
was	O
not	O
evident	O
in	O
the	O
KO	O
‐	O
HFD	O
mice	B-OG
(	O
Fig	O
.	O
1E	O
).	O

Furthermore	O
,	O
mRNA	O
levels	O
of	O
collagen	B-GP
I	I-GP
and	O
collagen	B-GP
IV	I-GP
,	O
and	O
transforming	B-GP
growth	I-GP
factor	I-GP
‐	I-GP
β1	I-GP
(	O
TGF	B-GP
‐	I-GP
β1	I-GP
)	O
were	O
increased	O
in	O
B6	O
‐	O
HFD	O
mice	B-OG
but	O
showed	O
no	O
alteration	O
in	O
the	O
KO	O
‐	O
HFD	O
mice	B-OG
(	O
Fig	O
.	O
2A	O
–	O
C	O
).	O

Lack	O
of	O
renal	O
tissue	O
inflammation	O
in	O
MD2	B-GP
knockout	O
mice	B-OG
maintained	O
on	O
high	O
fat	O
diet	O
.	O

(	O
A	O
‐	O
C	O
)	O
Real	O
‐	O
time	O
quantitative	O
PCR	O
analysis	O
of	O
Collagen	B-GP
I	I-GP
(	O
A	O
),	O
Collagen	B-GP
IV	I-GP
(	O
B	O
)	O
and	O
TGF	B-GP
‐	I-GP
β1	I-GP
(	O
C	O
)	O
mRNA	O
levels	O
in	O
kidney	O
tissues	O
of	O
wild	O
‐	O
type	O
B6	O
and	O
MD2	B-GP
KO	O
mice	B-OG
.	O

(	O
D	O
,	O
E	O
)	O
Serum	O
levels	O
of	O
TNF	B-GP
‐	I-GP
α	I-GP
(	O
D	O
)	O
and	O
IL	B-GP
‐	I-GP
6	I-GP
(	O
E	O
)	O
in	O
kidney	O
tissue	O
homogenates	O
.	O

(	O
F	O
‐	O
I	O
)	O
PCR	O
analysis	O
of	O
inflammatory	O
mediators	O
showing	O
TNF	B-GP
‐	I-GP
α	I-GP
(	O
F	O
),	O
IL	B-GP
‐	I-GP
6	I-GP
(	O
G	O
),	O
IL	B-GP
‐	I-GP
1β	I-GP
(	O
H	O
)	O
and	O
VCAM	B-GP
‐	I-GP
1	I-GP
(	O
I	O
)	O
mRNA	O
levels	O
.	O

(	O
J	O
)	O
Representative	O
microscopic	O
images	O
showing	O
TNF	B-GP
‐	I-GP
α	I-GP
and	O
CD68	B-GP
immunohistochemistry	O
(	O
brown	O
colour	O
).	O

An	O
amplified	O
image	O
and	O
a	O
quantitative	O
result	O
for	O
TNF	B-GP
‐	I-GP
α	I-GP
staining	O
were	O
shown	O
in	O
the	O
Figure	O
S4	O
.	O

[	O
mRNA	O
levels	O
normalized	O
to	O
β	B-GP
‐	I-GP
actin	I-GP
;	O
mean	O
±	O
S	O
.	O
E	O
.	O
M	O
.;	O
n	O
=	O
7	O
/	O
8	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
,	O
B6	O
‐	O
HFD	O
versus	O
KO	O
‐	O
HFD	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
,	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
###	O
P	O
<	O
0	O
.	O
001	O
,	O
B6	O
‐	O
Ctrol	O
versus	O
B6	O
‐	O
HFD	O
].	O

Glomerulopathy	B-DS
in	O
obesity	B-DS
is	O
associated	O
with	O
an	O
inflammatory	O
state	O
of	O
the	O
kidney	O
3	O
.	O

We	O
have	O
recently	O
shown	O
increased	O
production	O
of	O
pro	O
‐	O
inflammatory	O
factors	O
in	O
the	O
kidney	O
tissues	O
of	O
mice	B-OG
maintained	O
on	O
HFD	O
11	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
preserved	O
renal	O
function	O
and	O
inhibited	O
tissue	O
remodelling	O
observed	O
in	O
MD2	B-GP
KO	O
mice	B-OG
on	O
HFD	O
is	O
associated	O
with	O
reduced	O
inflammatory	O
activity	O
.	O

Indeed	O
,	O
our	O
results	O
show	O
no	O
alteration	O
in	O
serum	O
levels	O
of	O
tumour	B-GP
necrosis	I-GP
factor	I-GP
‐	I-GP
α	I-GP
(	O
TNF	B-GP
‐	I-GP
α	I-GP
)	O
and	O
interleukin	B-GP
‐	I-GP
6	I-GP
(	O
IL	B-GP
‐	I-GP
6	I-GP
)	O
in	O
KO	O
‐	O
HFD	O
mice	B-OG
compared	O
to	O
KO	O
mice	B-OG
fed	O
the	O
control	O
diet	O
(	O
Fig	O
.	O
2D	O
and	O
E	O
).	O

mRNA	O
levels	O
of	O
cytokines	B-GP
in	O
KO	O
‐	O
HFD	O
,	O
including	O
TNF	B-GP
‐	I-GP
α	I-GP
,	O
IL	B-GP
‐	I-GP
6	I-GP
,	O
IL	B-GP
‐	I-GP
1β	I-GP
and	O
adhesion	B-GP
molecule	I-GP
,	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
‐	I-GP
1	I-GP
(	O
VCAM	B-GP
‐	I-GP
1	I-GP
)	O
also	O
remained	O
at	O
levels	O
comparable	O
to	O
KO	O
mice	B-OG
on	O
control	O
diet	O
(	O
Fig	O
.	O
2F	O
–	O
I	O
).	O

Immunohistochemical	O
staining	O
showed	O
increased	O
TNF	B-GP
‐	I-GP
α	I-GP
and	O
macrophage	O
marker	O
CD68	B-GP
immunoreactivity	O
in	O
the	O
kidney	O
tissues	O
of	O
the	O
B6	O
‐	O
HFD	O
mice	B-OG
(	O
Fig	O
.	O
2J	O
and	O
Fig	O
.	O
S4	O
).	O

The	O
staining	O
was	O
dramatically	O
lower	O
in	O
the	O
KO	O
‐	O
HFD	O
mice	B-OG
.	O

As	O
these	O
cytokines	B-GP
and	O
adhesion	B-GP
molecule	I-GP
are	O
elevated	O
only	O
in	O
the	O
B6	B-OG
mice	I-OG
on	O
HFD	O
,	O
the	O
results	O
clearly	O
show	O
inhibited	O
inflammatory	O
activity	O
in	O
the	O
MD2	B-GP
deficient	O
mice	B-OG
.	O

Inhibiting	O
MD2	B-GP
by	O
small	O
‐	O
molecule	O
inhibitor	O
prevents	O
development	O
of	O
kidney	O
dysfunction	O
in	O
HFD	O
‐	O
induced	O
model	O
of	O
obesity	B-DS

Our	O
studies	O
in	O
MD2	B-GP
KO	O
mice	B-OG
show	O
that	O
MD2	B-GP
activity	O
is	O
involved	O
in	O
HFD	O
‐	O
induced	O
obesity	B-DS
and	O
associated	O
renal	O
dysfunction	O
.	O

To	O
build	O
on	O
these	O
results	O
,	O
we	O
tested	O
whether	O
we	O
can	O
prevent	O
obesity	B-DS
‐	O
associated	O
renal	O
dysfunction	O
using	O
another	O
approach	O
to	O
inhibit	O
MD2	B-GP
.	O

We	O
used	O
a	O
small	O
‐	O
molecule	O
inhibitor	O
of	O
MD2	B-GP
,	O
L6H21	O
,	O
which	O
specifically	O
targets	O
MD2	B-GP
through	O
direct	O
binding	O
32	O
.	O

Curcumin	O
is	O
a	O
well	O
‐	O
known	O
natural	O
product	O
with	O
anti	O
‐	O
inflammatory	O
activity	O
and	O
exhibits	O
anti	O
‐	O
inflammatory	O
activity	O
and	O
inhibits	O
HFD	O
‐	O
induced	O
renal	B-DS
inflammation	I-DS
and	O
injuries	O
33	O
,	O
34	O
,	O
35	O
.	O

Here	O
,	O
curcumin	O
was	O
used	O
as	O
a	O
positive	O
comparison	O
.	O

We	O
performed	O
similar	O
studies	O
with	O
L6H21	O
as	O
with	O
the	O
MD2	B-GP
KO	O
mice	B-OG
.	O

For	O
this	O
study	O
,	O
MD2	B-GP
inhibition	O
by	O
L6H21	O
administration	O
was	O
started	O
after	O
2	O
‐	O
month	O
HFD	O
feeding	O
.	O

We	O
also	O
tested	O
the	O
MD2	B-GP
expression	O
in	O
kidneys	O
of	O
mice	B-OG
fed	O
by	O
HFD	O
for	O
2	O
months	O
.	O

The	O
Figure	O
S5	O
showed	O
that	O
2	O
months	O
of	O
HFD	O
feeding	O
already	O
induced	O
MD2	B-GP
overexpression	O
and	O
MD2	B-GP
/	O
TLR4	B-GP
complex	O
formation	O
in	O
mouse	B-OG
kidneys	O
.	O

First	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
L6H21	O
on	O
hyperlipidemia	B-DS
in	O
B6	B-OG
mice	I-OG
on	O
HFD	O
.	O

Our	O
results	O
show	O
that	O
L6H21	O
did	O
not	O
affect	O
the	O
levels	O
of	O
LDL	O
,	O
TG	O
or	O
TCH	O
in	O
B6	B-OG
mice	I-OG
fed	O
a	O
HFD	O
(	O
Fig	O
.	O
S6	O
).	O

However	O
,	O
parameters	O
of	O
HFD	O
‐	O
associated	O
renal	O
dysfunction	O
including	O
increased	O
serum	O
creatinine	O
(	O
Fig	O
.	O
3A	O
)	O
and	O
urine	O
albumin	B-GP
(	O
Fig	O
.	O
3B	O
)	O
were	O
prevented	O
by	O
L6H21	O
.	O

L6H21	O
also	O
normalized	O
KW	O
/	O
BW	O
ratio	O
(	O
Fig	O
.	O
3C	O
)	O
and	O
reduced	O
measures	O
of	O
connective	O
tissue	O
deposition	O
in	O
mice	B-OG
fed	O
with	O
HFD	O
(	O
Fig	O
.	O
3D	O
and	O
Fig	O
.	O
S7	O
).	O

These	O
results	O
show	O
that	O
MD2	B-GP
inhibition	O
ameliorated	O
HFD	O
‐	O
induced	O
structural	O
and	O
functional	O
alterations	O
in	O
the	O
kidney	O
.	O

MD2	B-GP
inhibition	O
by	O
L6H21	O
protects	O
against	O
high	O
fat	O
diet	O
‐	O
induced	O
kidney	O
remodelling	O
and	O
inflammation	O
.	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
fed	O
a	O
HFD	O
or	O
control	O
diet	O
(	O
ctrol	O
)	O
for	O
2	O
months	O
.	O

Mice	B-OG
were	O
then	O
treated	O
with	O
L6H21	O
every	O
2	O
days	O
for	O
2	O
months	O
and	O
kidney	O
tissues	O
were	O
evaluated	O
.	O

(	O
A	O
)	O
Serum	O
creatinine	O
levels	O
in	O
kidney	O
tissue	O
homogenates	O
.	O

(	O
B	O
)	O
Urine	O
albumin	B-GP
levels	O
after	O
2	O
months	O
of	O
treatment	O
with	O
L6H21	O
.	O

(	O
C	O
)	O
Kidney	O
weights	O
normalized	O
to	O
body	O
weight	O
.	O

(	O
D	O
)	O
Representative	O
microscopic	O
images	O
of	O
H	O
&	O
E	O
,	O
Masson	O
'	O
s	O
trichrome	O
stain	O
(	O
blue	O
colour	O
),	O
Sirius	O
Red	O
stain	O
(	O
red	O
colour	O
)	O
and	O
immunohistochemical	O
staining	O
for	O
TNF	B-GP
‐	I-GP
α	I-GP
(	O
brown	O
colour	O
).	O

The	O
quantitative	O
data	O
for	O
1E	O
were	O
shown	O
in	O
the	O
Figure	O
S7	O
.	O

(	O
E	O
‐	O
H	O
)	O
PCR	O
analysis	O
of	O
inflammatory	O
genes	O
showing	O
TNF	B-GP
‐	I-GP
α	I-GP
and	O
IL	B-GP
‐	I-GP
6	I-GP
(	O
E	O
),	O
IL	B-GP
‐	I-GP
1β	I-GP
(	O
F	O
),	O
VCAM	B-GP
‐	I-GP
1	I-GP
(	O
G	O
)	O
and	O
ICAM	B-GP
‐	I-GP
1	I-GP
(	O
H	O
)	O
mRNA	O
levels	O
in	O
kidney	O
tissues	O
of	O
B6	B-OG
mice	I-OG
.	O

(	O
I	O
)	O
Representative	O
Western	O
blot	O
analysis	O
of	O
inflammatory	O
signalling	O
pathway	O
activation	O
.	O

[	O
Cur	O
=	O
curcumin	O
/	O
positive	O
control	O
;	O
mRNA	O
levels	O
normalized	O
to	O
β	B-GP
‐	I-GP
actin	I-GP
;	O
means	O
±	O
S	O
.	O
E	O
.	O
M	O
.;	O
n	O
=	O
7	O
/	O
8	O
in	O
four	O
groups	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
versus	O
HFD	O
].	O

We	O
next	O
assessed	O
indices	O
of	O
inflammation	O
in	O
the	O
kidney	O
tissues	O
of	O
B6	B-OG
mice	I-OG
treated	O
with	O
L6H21	O
.	O

Anti	O
‐	O
CD68	B-GP
immunofluorescence	O
staining	O
analysis	O
showed	O
that	O
L6H21	O
blocked	O
HFD	O
‐	O
induced	O
macrophage	O
infiltration	O
in	O
mouse	B-OG
kidney	O
(	O
Fig	O
.	O
S8	O
).	O

TNF	B-GP
‐	I-GP
α	I-GP
immunoreactivity	O
in	O
renal	O
tissues	O
of	O
B6	B-OG
mice	I-OG
maintained	O
on	O
HFD	O
and	O
treated	O
with	O
L6H21	O
was	O
comparable	O
to	O
mice	B-OG
fed	O
normal	O
control	O
diet	O
(	O
Fig	O
.	O
3D	O
and	O
Fig	O
.	O
S7	O
).	O

This	O
result	O
correlated	O
with	O
mRNA	O
levels	O
of	O
TNF	B-GP
‐	I-GP
α	I-GP
(	O
Fig	O
.	O
3E	O
)	O
and	O
other	O
cytokines	B-GP
including	O
IL	B-GP
‐	I-GP
6	I-GP
and	O
IL	B-GP
‐	I-GP
1β	I-GP
(	O
Fig	O
.	O
3E	O
–	O
F	O
).	O

Similarly	O
,	O
we	O
found	O
that	O
mRNA	O
and	O
protein	O
levels	O
of	O
adhesion	B-GP
molecules	I-GP
VCAM	B-GP
‐	I-GP
1	I-GP
and	O
ICAM	B-GP
‐	I-GP
1	I-GP
and	O
chemokine	B-GP
MCP	B-GP
‐	I-GP
1	I-GP
in	O
HFD	O
mice	B-OG
treated	O
with	O
L6H21	O
were	O
comparable	O
to	O
mice	B-OG
on	O
control	O
diet	O
(	O
Fig	O
.	O
3G	O
–	O
I	O
and	O
Fig	O
.	O
S9	O
).	O

These	O
results	O
indicate	O
that	O
L6H21	O
prevented	O
HFD	O
‐	O
induced	O
renal	O
dysfunction	O
possibly	O
through	O
dampening	O
inflammatory	O
activity	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
activity	O
of	O
signalling	O
proteins	O
involved	O
in	O
the	O
expression	O
of	O
pro	O
‐	O
inflammatory	O
molecules	O
.	O

Studies	O
have	O
shown	O
that	O
MAPK	B-GP
and	O
NF	B-GP
‐	I-GP
κB	I-GP
are	O
downstream	O
of	O
MD2	B-GP
/	O
TLR4	B-GP
complex	O
and	O
these	O
signalling	O
pathways	O
are	O
also	O
the	O
predominant	O
ones	O
activated	O
in	O
renal	O
tissue	O
in	O
mice	B-OG
on	O
HFD	O
9	O
,	O
11	O
.	O

We	O
found	O
reduced	O
phosphorylation	O
and	O
degradation	O
of	O
IκB	B-GP
‐	I-GP
α	I-GP
in	O
L6H21	O
‐	O
treated	O
mice	B-OG
fed	O
a	O
HFD	O
compared	O
to	O
HFD	O
alone	O
group	O
(	O
Fig	O
.	O
3I	O
).	O

Additionally	O
,	O
L6H21	O
prevented	O
the	O
HFD	O
‐	O
associated	O
increased	O
phosphorylation	O
of	O
ERK	B-GP
,	O
p38	B-GP
and	O
JNK	B-GP
in	O
renal	O
tissues	O
(	O
Fig	O
.	O
3I	O
).	O

PA	O
induces	O
MD2	B-GP
‐	O
dependent	O
renal	O
inflammatory	O
injury	O
in	O
vivo	O

Elevated	O
fatty	O
acids	O
in	O
the	O
HFD	O
‐	O
fed	O
mice	B-OG
may	O
have	O
mediated	O
inflammatory	O
activity	O
in	O
the	O
kidney	O
tissues	O
leading	O
to	O
tissue	O
structural	O
and	O
functional	O
alterations	O
.	O

We	O
measured	O
local	O
level	O
of	O
free	O
fatty	O
acids	O
(	O
FFAs	O
)	O
in	O
kidney	O
tissues	O
of	O
mice	B-OG
fed	O
a	O
HFD	O
and	O
show	O
elevated	O
levels	O
(	O
Fig	O
.	O
S10	O
).	O

To	O
explore	O
a	O
potential	O
mechanistic	O
role	O
,	O
we	O
challenged	O
wild	O
‐	O
type	O
B6	O
and	O
MD2	B-GP
KO	O
mice	B-OG
with	O
PA	O
,	O
the	O
most	O
predominant	O
saturated	O
FFA	O
which	O
plays	O
a	O
detrimental	O
role	O
in	O
tissues	O
when	O
excessed	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
.	O

Here	O
,	O
a	O
significant	O
limitation	O
in	O
Figure	O
S10	O
is	O
that	O
we	O
did	O
not	O
directly	O
measure	O
the	O
PA	O
(	O
or	O
total	O
saturated	O
FFAs	O
)	O
level	O
in	O
kidneys	O
from	O
control	O
and	O
HFD	O
mice	B-OG
.	O

As	O
expected	O
,	O
we	O
found	O
that	O
B6	B-OG
mice	I-OG
challenged	O
with	O
PA	O
developed	O
kidney	O
weight	O
increase	O
(	O
Fig	O
.	O
S11	O
)	O
and	O
renal	O
dysfunction	O
as	O
indicated	O
by	O
elevated	O
serum	O
creatinine	O
and	O
urine	O
urea	O
nitrogen	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
).	O

Microscopic	O
examination	O
revealed	O
increased	O
connective	O
tissue	O
deposition	O
in	O
PA	O
‐	O
challenged	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
4C	O
and	O
Fig	O
.	O
S12	O
).	O

Both	O
renal	O
dysfunction	O
measures	O
and	O
tissue	O
remodelling	O
were	O
not	O
observed	O
in	O
the	O
MD2	B-GP
KO	O
mice	B-OG
treated	O
with	O
PA	O
(	O
Fig	O
.	O
4A	O
–	O
C	O
and	O
Fig	O
.	O
S12	O
).	O

Furthermore	O
,	O
KO	O
mice	B-OG
treated	O
with	O
PA	O
presented	O
with	O
levels	O
of	O
TGF	B-GP
‐	I-GP
β1	I-GP
and	O
collagen	B-GP
I	I-GP
mRNA	O
that	O
were	O
comparable	O
to	O
that	O
of	O
control	O
(	O
Fig	O
.	O
S13A	O
and	O
B	O
).	O

Palmitic	O
acid	O
induces	O
MD2	B-GP
‐	O
dependent	O
renal	O
dysfunction	O
and	O
tissue	O
remodelling	O
in	O
vivo	O
.	O

Wild	O
‐	O
type	O
(	O
B6	O
)	O
and	O
MD2	B-GP
−/−	O
mice	B-OG
(	O
KO	O
)	O
were	O
challenged	O
with	O
palmitic	O
acid	O
(	O
PA	O
)	O
twice	O
daily	O
for	O
2	O
weeks	O
and	O
urine	O
samples	O
and	O
kidney	O
tissues	O
collected	O
for	O
analysis	O
.	O

(	O
A	O
)	O
Serum	O
creatinine	O
levels	O
in	O
mice	B-OG
challenged	O
with	O
PA	O
.	O

(	O
B	O
)	O
Urine	O
urea	O
nitrogen	O
levels	O
.	O

(	O
C	O
)	O
Representative	O
histochemical	O
assessment	O
of	O
kidney	O
tissue	O
morphology	O
by	O
H	O
&	O
E	O
,	O
and	O
fibrosis	O
by	O
Masson	O
'	O
s	O
trichrome	O
and	O
Sirius	O
Red	O
staining	O
.	O

The	O
quantitative	O
data	O
for	O
1E	O
were	O
shown	O
in	O
the	O
Figure	O
S12	O
.	O

(	O
D	O
‐	O
F	O
)	O
Pro	B-GP
‐	I-GP
inflammatory	I-GP
cytokines	I-GP
in	O
kidney	O
tissues	O
of	O
PA	O
‐	O
challenged	O
mice	B-OG
showing	O
TNF	B-GP
‐	I-GP
α	I-GP
(	O
D	O
),	O
IL	B-GP
‐	I-GP
6	I-GP
(	O
E	O
)	O
and	O
chemotactic	O
factor	O
MCP	B-GP
‐	I-GP
1	I-GP
(	O
F	O
).	O

(	O
mRNA	O
levels	O
normalized	O
to	O
β	B-GP
‐	I-GP
actin	I-GP
;	O
mean	O
±	O
S	O
.	O
E	O
.	O
M	O
.;	O
n	O
=	O
8	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
***	O
P	O
<	O
0	O
.	O
001	O
,	O
KO	O
‐	O
PA	O
versus	O
B6	O
‐	O
PA	O
;	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
###	O
P	O
<	O
0	O
.	O
001	O
,	O
B6	O
‐	O
NS	O
versus	O
B6	O
‐	O
PA	O
).	O

We	O
next	O
examined	O
pro	O
‐	O
inflammatory	O
factor	O
expression	O
in	O
PA	O
‐	O
challenged	O
mice	B-OG
and	O
show	O
increased	O
TNF	B-GP
‐	I-GP
α	I-GP
,	O
IL	B-GP
‐	I-GP
6	I-GP
and	O
MCP	B-GP
‐	I-GP
1	I-GP
protein	O
in	O
B6	B-OG
mice	I-OG
(	O
Fig	O
.	O
4D	O
–	O
F	O
).	O

However	O
,	O
this	O
induction	O
was	O
not	O
observed	O
in	O
the	O
KO	O
mice	B-OG
.	O

PA	O
also	O
induced	O
renal	O
tissue	O
mRNA	O
expression	O
of	O
cytokines	B-GP
and	O
adhesion	B-GP
molecules	I-GP
in	O
B6	B-OG
mice	I-OG
but	O
not	O
the	O
MD2	B-GP
KO	O
mice	B-OG
(	O
Fig	O
.	O
S13C	O
–	O
G	O
).	O

The	O
up	O
‐	O
regulation	O
of	O
adhesion	B-GP
molecules	I-GP
in	O
the	O
renal	O
tissue	O
suggests	O
recruitment	O
of	O
infiltrating	O
leucocytes	O
.	O

We	O
found	O
TNF	B-GP
‐	I-GP
α	I-GP
to	O
demark	O
the	O
interstitial	O
‐	O
tubular	O
sites	O
of	O
the	O
kidney	O
and	O
as	O
expected	O
,	O
CD68	B-GP
was	O
also	O
detected	O
in	O
mice	B-OG
treated	O
with	O
PA	O
(	O
Fig	O
.	O
S13H	O
).	O

Importantly	O
,	O
PA	O
‐	O
induced	O
TNF	B-GP
‐	I-GP
α	I-GP
and	O
CD68	B-GP
immunoreactivity	O
was	O
reduced	O
in	O
KO	O
mice	B-OG
(	O
Figs	O
S13H	O
and	O
S14	O
).	O

Inflammatory	O
locus	O
of	O
tubular	O
epithelial	O
cells	O
and	O
mesangial	O
cells	O
is	O
MD2	B-GP
‐	O
dependent	O

To	O
gain	O
insight	O
into	O
target	O
cells	O
of	O
HFD	O
‐	O
and	O
PA	O
‐	O
induced	O
renal	O
damage	O
,	O
we	O
investigated	O
renal	O
tubular	O
epithelial	O
cells	O
(	O
NRK52E	O
)	O
and	O
renal	O
mesangial	O
cells	O
(	O
SV40	B-OG
).	O

We	O
stimulated	O
NRK52E	O
cells	O
with	O
100	O
μM	O
PA	O
and	O
assessed	O
the	O
activation	O
of	O
signalling	O
proteins	O
in	O
the	O
MD2	B-GP
/	O
TLR4	B-GP
pathway	O
.	O

PA	O
‐	O
activated	O
NF	B-GP
‐	I-GP
κB	I-GP
as	O
shown	O
by	O
increased	O
IκB	B-GP
‐	I-GP
α	I-GP
degradation	O
and	O
NF	B-GP
‐	I-GP
kB	I-GP
p65	B-GP
translocation	O
from	O
the	O
cytosol	O
to	O
nucleus	O
.	O

In	O
addition	O
,	O
PA	O
activated	O
the	O
three	O
arms	O
of	O
the	O
MAPK	B-GP
pathway	O
(	O
ERK	B-GP
,	O
JNK	B-GP
and	O
p38	B-GP
)	O
(	O
Fig	O
.	O
5A	O
).	O

Activation	O
of	O
these	O
pathways	O
was	O
associated	O
with	O
increased	O
mRNA	O
levels	O
of	O
TNF	B-GP
‐	I-GP
α	I-GP
,	O
IL	B-GP
‐	I-GP
6	I-GP
and	O
IL	B-GP
‐	I-GP
1β	I-GP
(	O
Fig	O
.	O
5B	O
).	O

PA	O
‐	O
induced	O
signalling	O
protein	O
activation	O
and	O
cytokine	B-GP
up	O
‐	O
regulation	O
were	O
effectively	O
prevented	O
by	O
L6H21	O
(	O
Fig	O
.	O
5A	O
and	O
B	O
).	O

Additionally	O
,	O
PA	O
‐	O
activated	O
NRK52E	O
cells	O
presented	O
with	O
increased	O
mRNA	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
(	O
ICAM	B-GP
‐	I-GP
1	I-GP
and	O
VCAM	B-GP
‐	I-GP
1	I-GP
)	O
and	O
chemoattractant	O
MCP	B-GP
‐	I-GP
1	I-GP
(	O
Fig	O
.	O
5C	O
),	O
and	O
the	O
corresponding	O
proteins	O
(	O
Fig	O
.	O
5D	O
).	O

We	O
also	O
found	O
that	O
PA	O
‐	O
stimulated	O
NRK52E	O
cells	O
were	O
more	O
adhesive	O
to	O
rat	B-OG
primary	O
macrophages	O
(	O
Fig	O
.	O
5E	O
).	O

Pre	O
‐	O
treatment	O
of	O
NRK52E	O
cells	O
with	O
L6H21	O
significantly	O
inhibited	O
adhesion	B-GP
molecule	I-GP
up	O
‐	O
regulation	O
in	O
a	O
dose	O
‐	O
dependent	O
manner	O
and	O
remarkably	O
prevented	O
macrophage	O
adhesion	O
in	O
NRK52E	O
cells	O
(	O
Fig	O
.	O
5C	O
–	O
E	O
).	O

Similar	O
results	O
were	O
observed	O
in	O
mouse	B-OG
SV40	B-OG
mesangial	O
cells	O
(	O
Fig	O
.	O
S15	O
).	O

These	O
results	O
indicate	O
that	O
PA	O
induces	O
MD2	B-GP
‐	O
dependent	O
inflammation	O
in	O
renal	O
tubular	O
cells	O
and	O
mesangial	O
cells	O
.	O

Palmitic	O
acid	O
activates	O
MD2	B-GP
‐	O
dependent	O
inflammatory	O
activity	O
in	O
NRK52E	O
cells	O
.	O

Rat	B-OG
kidney	O
epithelial	O
cells	O
NRK52E	O
were	O
exposed	O
to	O
PA	O
for	O
indicated	O
times	O
with	O
or	O
without	O
1	O
hrs	O
pre	O
‐	O
treatment	O
with	O
L6H21	O
.	O

(	O
A	O
)	O
Representative	O
Western	O
blot	O
analysis	O
of	O
NFκB	B-GP
and	O
MAPK	B-GP
activation	O
by	O
PA	O
showing	O
IκB	B-GP
‐	I-GP
α	I-GP
,	O
nuclear	O
p65	B-GP
and	O
cytosolic	O
p65	B-GP
(	O
following	O
nuclear	O
protein	O
extraction	O
),	O
p	O
‐	O
ERK	B-GP
,	O
p	O
‐	O
JNK	B-GP
and	O
p	O
‐	O
p38	B-GP
in	O
NRK52E	O
cells	O
(	O
30	O
min	O
.	O
PA	O
exposure	O
).	O

(	O
B	O
)	O
qPCR	O
analysis	O
of	O
inflammatory	B-GP
cytokines	I-GP
showing	O
TNF	B-GP
‐	I-GP
α	I-GP
,	O
IL	B-GP
‐	I-GP
6	I-GP
and	O
IL	B-GP
‐	I-GP
1β	I-GP
mRNA	O
levels	O
in	O
NRK52E	O
cells	O
stimulated	O
with	O
PA	O
for	O
6	O
hrs	O
.	O

(	O
C	O
)	O
mRNA	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
(	O
ICAM	B-GP
‐	I-GP
1	I-GP
and	O
VCAM	B-GP
‐	I-GP
1	I-GP
)	O
and	O
MCP	B-GP
‐	I-GP
1	I-GP
in	O
NRK52E	O
cells	O
stimulated	O
with	O
PA	O
for	O
6	O
hrs	O
.	O

(	O
D	O
)	O
Representative	O
Western	O
blot	O
of	O
ICAM	B-GP
‐	I-GP
1	I-GP
and	O
VCAM	B-GP
‐	I-GP
1	I-GP
in	O
NRK52E	O
cells	O
stimulated	O
with	O
PA	O
for	O
12	O
hrs	O
.	O

(	O
E	O
)	O
Rat	B-OG
primary	O
macrophage	O
adhesion	O
to	O
PA	O
‐	O
treated	O
NRK52E	O
cells	O
as	O
assessed	O
through	O
CD68	B-GP
staining	O
(	O
Red	O
).	O

[	O
mRNA	O
normalized	O
to	O
β	B-GP
‐	I-GP
actin	I-GP
;	O
means	O
±	O
S	O
.	O
E	O
.	O
M	O
.;	O
n	O
=	O
3	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
,	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
and	O
###	O
P	O
<	O
0	O
.	O
001	O
versus	O
DMSO	O
.]	O

Discussion	O

Obesity	B-DS
is	O
associated	O
with	O
the	O
development	O
of	O
kidney	B-DS
disease	I-DS
,	O
and	O
there	O
is	O
an	O
urgent	O
need	O
to	O
understand	O
the	O
pathogenic	O
drivers	O
of	O
injury	O
progression	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
used	O
established	O
mouse	B-OG
models	O
of	O
obesity	B-DS
to	O
test	O
a	O
novel	O
mechanism	O
centred	O
on	O
inflammatory	O
injury	O
.	O

Our	O
results	O
showed	O
that	O
kidneys	O
in	O
obese	O
mice	B-OG
express	O
more	O
MD2	B-GP
protein	O
.	O

Renal	O
tissue	O
inflammation	O
,	O
tissue	O
remodelling	O
and	O
functional	O
alterations	O
did	O
not	O
occur	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
when	O
MD2	B-GP
gene	O
was	O
disrupted	O
or	O
pharmacologically	O
inhibited	O
.	O

We	O
also	O
found	O
that	O
PA	O
mimicked	O
HFD	O
and	O
PA	O
‐	O
induced	O
alterations	O
were	O
also	O
inhibited	O
by	O
MD2	B-GP
.	O

Our	O
study	O
suggests	O
that	O
MD2	B-GP
is	O
essential	O
for	O
the	O
development	O
and	O
the	O
progression	O
of	O
renal	O
inflammatory	O
injury	O
in	O
obesity	B-DS
.	O

Mice	B-OG
fed	O
a	O
HFD	O
presented	O
with	O
a	O
greater	O
KW	O
/	O
BW	O
ratio	O
than	O
mice	B-OG
fed	O
the	O
standard	O
chow	O
.	O

This	O
ratio	O
was	O
maintained	O
despite	O
a	O
steady	O
gain	O
of	O
body	O
weight	O
.	O

Importantly	O
,	O
the	O
KW	O
/	O
BW	O
ratio	O
in	O
the	O
KO	O
‐	O
HFD	O
mice	B-OG
was	O
comparable	O
to	O
MD2	B-GP
control	O
diet	O
mice	B-OG
.	O

This	O
suggests	O
that	O
the	O
kidney	O
weight	O
gain	O
was	O
pathological	O
,	O
and	O
not	O
attributed	O
to	O
normal	O
adaptive	O
growth	O
stimulated	O
by	O
diet	O
.	O

A	O
characteristic	O
lesion	O
associated	O
with	O
obesity	B-DS
is	O
glomerulomegaly	B-DS
and	O
glomerulosclerosis	B-DS
,	O
manifesting	O
as	O
increased	O
deposition	O
of	O
connective	O
tissue	O
matrix	O
,	O
cellular	O
proliferation	O
and	O
leucocytic	O
infiltration	O
2	O
,	O
10	O
,	O
36	O
.	O

Our	O
histological	O
analyses	O
of	O
renal	O
tissue	O
from	O
mice	B-OG
on	O
HFD	O
or	O
with	O
increased	O
circulating	O
PA	O
are	O
consistent	O
with	O
this	O
type	O
of	O
tissue	O
remodelling	O
.	O

We	O
have	O
shown	O
increased	O
deposition	O
of	O
collagen	B-GP
and	O
glycogen	O
as	O
well	O
as	O
increased	O
macrophage	O
infiltration	O
.	O

These	O
pathological	O
tissue	O
changes	O
are	O
not	O
evident	O
in	O
the	O
MD2	B-GP
knockout	O
mice	B-OG
or	O
mice	B-OG
with	O
pharmacological	O
MD2	B-GP
inhibition	O
.	O

A	O
crucial	O
component	O
of	O
the	O
renal	O
inflammatory	O
injury	O
is	O
leucocytic	O
extravasation	O
and	O
infiltration	O
into	O
the	O
renal	O
tissue	O
sites	O
.	O

Macrophage	O
infiltration	O
,	O
as	O
indicated	O
by	O
increased	O
CD68	B-GP
localization	O
in	O
renal	O
tissue	O
,	O
occurred	O
in	O
mice	B-OG
fed	O
a	O
HFD	O
or	O
challenged	O
with	O
PA	O
.	O

Infiltrated	O
macrophages	O
that	O
take	O
up	O
residence	O
in	O
the	O
renal	O
tissue	O
are	O
likely	O
to	O
be	O
highly	O
activated	O
,	O
secreting	O
pro	B-GP
‐	I-GP
inflammatory	I-GP
cytokines	I-GP
,	O
chemoattractants	O
,	O
growth	O
factors	O
and	O
damaging	O
oxidants	O
.	O

This	O
in	O
turn	O
may	O
create	O
a	O
vicious	O
positive	O
feedback	O
system	O
to	O
recruit	O
other	O
leucocytes	O
and	O
produce	O
more	O
pro	O
‐	O
inflammatory	O
molecules	O
.	O

Our	O
results	O
suggest	O
that	O
,	O
at	O
least	O
,	O
renal	O
tubular	O
cells	O
,	O
mesangial	O
cells	O
and	O
macrophages	O
could	O
contribute	O
significantly	O
to	O
this	O
positive	O
feedback	O
cycle	O
of	O
inflammation	O
in	O
renal	O
tissue	O
.	O

We	O
observed	O
that	O
macrophages	O
adhered	O
to	O
PA	O
‐	O
stimulated	O
tubular	O
cells	O
and	O
mesangial	O
cells	O
in	O
culture	O
.	O

Activated	O
tubular	O
or	O
mesangial	O
cells	O
may	O
provide	O
a	O
recruiting	O
platform	O
for	O
macrophages	O
into	O
kidney	O
tissue	O
sites	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
all	O
of	O
three	O
cell	O
types	O
were	O
potently	O
activated	O
by	O
PA	O
to	O
produce	O
cytokines	B-GP
,	O
chemokines	B-GP
,	O
and	O
induce	O
adhesion	B-GP
molecules	I-GP
.	O

We	O
believe	O
that	O
this	O
may	O
create	O
a	O
MD2	B-GP
‐	O
dependent	O
locus	O
of	O
inflammatory	O
activity	O
.	O

In	O
addition	O
,	O
blockade	O
of	O
TLR4	B-GP
signalling	O
should	O
improve	O
insulin	B-GP
sensitivity	O
in	O
HFD	O
‐	O
treated	O
mice	B-OG
.	O

Thus	O
,	O
MD2	B-GP
blockage	O
may	O
also	O
improve	O
the	O
insulin	B-GP
sensitivity	O
here	O
.	O

Although	O
the	O
protection	O
of	O
MD2	B-GP
blockage	O
against	O
renal	O
injury	O
is	O
accompanied	O
with	O
the	O
inhibition	O
of	O
inflammation	O
in	O
mice	B-OG
,	O
it	O
is	O
difficult	O
to	O
exclude	O
the	O
effects	O
of	O
improved	O
insulin	B-GP
sensitivity	O
on	O
renal	O
protection	O
.	O

In	O
order	O
to	O
ascribe	O
the	O
renal	O
protection	O
to	O
inflammatory	O
inhibition	O
,	O
we	O
used	O
the	O
in	O
vitro	O
study	O
in	O
renal	O
cells	O
(	O
NRK	O
‐	O
52E	O
and	O
SV40	B-OG
),	O
in	O
which	O
,	O
MD2	B-GP
inhibition	O
directly	O
blocked	O
the	O
inflammation	O
induced	O
by	O
PA	O
stimulation	O
.	O

We	O
think	O
that	O
the	O
anti	O
‐	O
inflammatory	O
effect	O
of	O
TLR4	B-GP
/	O
MD2	B-GP
blockage	O
may	O
be	O
the	O
most	O
upstream	O
mechanism	O
for	O
the	O
phenotypic	O
protections	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
,	O
including	O
renal	O
injury	O
in	O
HFD	O
mice	B-OG
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
improvement	O
on	O
insulin	B-GP
sensitivity	O
by	O
TLR4	B-GP
/	O
MD2	B-GP
blockage	O
also	O
results	O
from	O
the	O
inflammatory	O
decrease	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
.	O

Also	O
,	O
it	O
is	O
interesting	O
that	O
the	O
triglycerides	O
are	O
not	O
elevated	O
in	O
MD2	B-GP
knockout	O
mice	B-OG
on	O
HFD	O
(	O
Fig	O
.	O
S2	O
).	O

This	O
prompts	O
the	O
question	O
whether	O
lowering	O
triglycerides	O
is	O
the	O
mechanism	O
of	O
renoprotective	O
action	O
of	O
MD	O
blockage	O
.	O

However	O
,	O
we	O
do	O
not	O
know	O
the	O
mechanism	O
yet	O
.	O

Such	O
notes	O
will	O
be	O
further	O
studied	O
by	O
us	O
in	O
the	O
future	O
.	O

Our	O
experimental	O
elevation	O
of	O
the	O
circulating	O
PA	O
,	O
a	O
predominant	O
SFA	O
,	O
in	O
mice	B-OG
resulted	O
in	O
inflammatory	O
renal	O
injury	O
mimicking	O
that	O
produced	O
by	O
HFD	O
.	O

We	O
acknowledge	O
that	O
it	O
will	O
be	O
better	O
to	O
measure	O
saturated	O
fatty	O
acids	O
or	O
PA	O
in	O
mouse	B-OG
kidney	O
tissues	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
any	O
commercial	O
kits	O
for	O
the	O
examination	O
of	O
PA	O
level	O
.	O

The	O
levels	O
of	O
FFA	O
in	O
control	O
kidney	O
and	O
obese	O
kidney	O
were	O
shown	O
in	O
the	O
Figure	O
S10	O
,	O
which	O
indicated	O
that	O
FFA	O
level	O
in	O
HFD	O
mouse	B-OG
kidney	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
control	O
mouse	B-OG
kidney	O
.	O

MD2	B-GP
knockout	O
mice	B-OG
were	O
protected	O
against	O
development	O
of	O
PA	O
‐	O
induced	O
renal	O
injury	O
.	O

These	O
finding	O
have	O
two	O
important	O
implications	O
:	O
i	O
)	O
PA	O
is	O
likely	O
a	O
predominant	O
SFA	O
responsible	O
for	O
the	O
HFD	O
‐	O
associated	O
renal	O
inflammatory	O
injury	O
;	O
and	O
ii	O
)	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
PA	O
induces	O
the	O
pathological	O
changes	O
were	O
mediated	O
mostly	O
through	O
MD2	B-GP
.	O

We	O
suspect	O
that	O
an	O
upstream	O
initiating	O
event	O
stimulated	O
by	O
PA	O
is	O
the	O
formation	O
of	O
the	O
MD2	B-GP
‐	O
TLR4	B-GP
complex	O
.	O

However	O
,	O
several	O
questions	O
remain	O
unanswered	O
and	O
should	O
be	O
the	O
focus	O
of	O
future	O
studies	O
.	O

For	O
example	O
,	O
the	O
elucidation	O
of	O
direct	O
cellular	O
targets	O
of	O
PA	O
in	O
kidney	O
tissue	O
.	O

In	O
addition	O
,	O
understanding	O
inflammatory	O
stress	O
‐	O
induced	O
cellular	O
activities	O
that	O
regulate	O
the	O
progression	O
towards	O
renal	O
injury	O
would	O
be	O
crucial	O
.	O

Studies	O
have	O
shown	O
that	O
many	O
,	O
if	O
not	O
all	O
,	O
cell	O
types	O
of	O
kidney	O
tissue	O
are	O
responsive	O
to	O
direct	O
stimulation	O
by	O
SFAs	O
.	O

These	O
cells	O
include	O
macrophages	O
14	O
,	O
mesangial	O
cells	O
7	O
,	O
vascular	O
endothelial	O
cells	O
20	O
,	O
podocytes	O
37	O
and	O
smooth	O
muscle	O
cells	O
13	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
unravel	O
this	O
complex	O
but	O
important	O
pathogenic	O
mechanism	O
of	O
obesity	B-DS
‐	O
associated	O
renal	O
injury	O
.	O

In	O
summary	O
,	O
our	O
results	O
confirm	O
that	O
HFD	O
induces	O
an	O
inflammatory	O
state	O
of	O
renal	O
tissue	O
,	O
with	O
progression	O
towards	O
renal	O
tissue	O
remodelling	O
and	O
functional	O
deficits	O
.	O

PA	O
,	O
the	O
most	O
predominant	O
circulating	O
SFA	O
,	O
is	O
the	O
likely	O
SFA	O
responsible	O
for	O
the	O
renal	O
tissue	O
inflammation	O
,	O
tissue	O
remodelling	O
,	O
and	O
dysfunction	O
observed	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
.	O

This	O
notion	O
is	O
supported	O
by	O
PA	O
‐	O
challenge	O
studies	O
which	O
recapitulated	O
HFD	O
‐	O
associate	O
phenotype	O
.	O

Importantly	O
,	O
we	O
conclude	O
that	O
MD2	B-GP
is	O
an	O
important	O
mediator	O
of	O
obesity	B-DS
‐	O
and	O
SFA	O
‐	O
induced	O
activation	O
of	O
pro	O
‐	O
inflammatory	O
signalling	O
pathways	O
MAPKs	B-GP
/	O
NF	B-GP
‐	I-GP
κB	I-GP
and	O
the	O
generation	O
of	O
inflammatory	O
molecules	O
.	O

Author	O
contributions	O

G	O
.	O
L	O
.,	O
Q	O
.	O
F	O
.	O
and	O
Y	O
.	O
W	O
.	O
contributed	O
to	O
experimental	O
design	O
.	O

Q	O
.	O
F	O
.,	O
L	O
.	O
W	O
.,	O
X	O
.	O
C	O
.,	O
D	O
.	O
Y	O
.,	O
Y	O
.	O
Z	O
.	O
and	O
P	O
.	O
Z	O
.	O
data	O
collection	O
.	O

J	O
.	O
W	O
.	O
and	O
Y	O
.	O
W	O
.	O
analysed	O
the	O
date	O
and	O
reviewed	O
the	O
article	O
.	O

H	O
.	O
L	O
.,	O
G	O
.	O
L	O
.	O
and	O
Y	O
.	O
W	O
.	O
wrote	O
the	O
article	O
.	O

Conflicts	O
of	O
interest	O

The	O
authors	O
confirm	O
that	O
there	O
are	O
no	O
conflicts	O
of	O
interest	O
.	O

Supporting	O
information	O

Data	O
S1	O
Materials	O
and	O
methods	O
.	O

Figure	O
S1	O
MD2	B-GP
expression	O
and	O
activation	O
in	O
the	O
kidney	O
tissues	O
of	O
high	O
fat	O
diet	O
(	O
HFD	O
)‐	O
fed	O
mices	B-OG

Figure	O
S2	O
MD2	B-GP
knockout	O
affects	O
serum	O
TG	O
,	O
but	O
not	O
LDL	O
and	O
TCH	O
,	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
.	O

Figure	O
S3	O
The	O
quantitative	O
data	O
for	O
the	O
staining	O
images	O
in	O
Figure	O
1G	O
.	O

Figure	O
S4	O
Upper	O
panel	O
:	O
an	O
amplified	O
image	O
(	O
400X	O
)	O
for	O
TNF	B-GP
‐	I-GP
α	I-GP
staining	O
in	O
Figure	O
2J	O
.	O

Figure	O
S5	O
MD2	B-GP
expression	O
and	O
activation	O
in	O
the	O
kidney	O
tissues	O
of	O
mice	B-OG
with	O
2	O
‐	O
month	O
HFD	O
feeding	O
.	O

Figure	O
S6	O
Administration	O
with	O
MD2	B-GP
inhibitor	O
L6H21	O
did	O
not	O
affect	O
serum	O
lipid	O
profile	O
in	O
HFD	O
‐	O
fed	O
mice	B-OG
.	O

Figure	O
S7	O
The	O
quantitative	O
data	O
for	O
the	O
staining	O
images	O
in	O
Figure	O
3D	O
.	O

Figure	O
S8	O
MD2	B-GP
inhibition	O
by	O
L6H21	O
prevents	O
macrophage	O
infiltration	O
in	O
HFD	O
kidney	O
.	O

Figure	O
S9	O
MD2	B-GP
inhibition	O
by	O
L6H21	O
prevents	O
high	O
fat	O
diet	O
‐	O
induced	O
MCP	B-GP
‐	I-GP
1	I-GP
expression	O
in	O
mouse	B-OG
kidney	O
.	O

Figure	O
S10	O
HFD	O
increases	O
FFA	O
levels	O
in	O
mouse	B-OG
kidney	O
tissues	O
.	O

Figure	O
S11	O
Palmitic	O
acid	O
injection	O
increases	O
kidney	O
weight	O
in	O
mice	B-OG
.	O

Figure	O
S12	O
The	O
quantitative	O
data	O
for	O
the	O
staining	O
images	O
in	O
Figure	O
4C	O
.	O

Figure	O
S13	O
Palmitic	O
acid	O
induces	O
MD2	B-GP
‐	O
dependent	O
renal	O
tissue	O
fibrosis	O
and	O
inflammation	O
in	O
vivo	O
.	O

Figure	O
S14	O
The	O
quantitative	O
data	O
for	O
the	O
staining	O
images	O
in	O
Figure	O
S6H	O

Figure	O
S15	O
PA	O
activates	O
MD2	B-GP
‐	O
dependent	O
inflammatory	O
activity	O
in	O
renal	O
mesangial	O
cells	O
.	O

Table	O
S1	O
Primers	O
used	O
for	O
real	O
‐	O
time	O
qPCR	O
assay	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

